Navigation Links
Orphan Drugs - Global Strategic Business Report
Date:12/4/2013

DUBLIN, December 4, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/9n9pzh/orphan_drugs) has announced the addition of the "Orphan Drugs - Global Strategic Business Report" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 113 companies including many key and niche players such as:

- AbbVie Inc.
- Actelion Pharmaceuticals Ltd.
- Amgen Inc.
- AstraZeneca plc
- Bayer HealthCare AG
- Biogen Idec Inc.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Celgene Corporation
- CEL-SCI Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Serono International S.A.
- Novartis AG
- Pfizer Inc.
- Recordati S.p.A.
- Orphan Europe
- Sanofi SA
- Genzyme Corporation.


Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For more information visit http://www.researchandmarkets.com/research/9n9pzh/orphan_drugs

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
2. Agility-PSR Wins "Best Contract Research Organization" in the 2013 ROAR Awards at the 4th Annual World Orphan Drug Conference in Geneva
3. CMC Contrast Granted Orphan Drug Designation by the FDA for its Liver Specific MRI Contrast Media CMC-001
4. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
5. FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
6. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
7. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
8. Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
9. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
10. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
11. Orphan Drugs for Cancer: R&D and Market 2013-2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... , June 14, 2017 The Bio ... City of Fremont and the ... the bio-pharma industry in California ... enabling executive networking, and fostering workforce development. The primary ... and growth of start-ups, as well as small and ...
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... 25, 2017 , ... Republicans in the United States Senate on Thursday released ... Care Reconciliation Act. It differs significantly from the American Health Care Act, which the ... committee, or the House will have to take up the Senate version as-is, if ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... offering genetic testing for medications in select Florida and Texas doctors' offices and ... , This new application of genetic testing recognizes the role genes play in ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality Institute ... Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate ... Alerts and Dashboards provide near real-time data about patients admitted to and/or discharged ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Military ... president's nominee for deputy secretary of Veterans Affairs, retired Marine Col. Thomas G. Bowman. ... Affairs. , Bowman brings an intimacy with the issues and challenges veterans ...
(Date:6/23/2017)... ... , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique approach ... proprietary technique that he calls the AuraLyft Facelift. The AuraLyft does more ... can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique approach ...
Breaking Medicine News(10 mins):